Please login to the form below

Not currently logged in
Email:
Password:

Bayer appoints president of Americas pharma business

Dr Carsten Brunn to lead operations across the US, Canada, Central and Latin America

Bayer Dr Carsten BrunnBayer has appointed Dr Carsten Brunn as the president of its pharmaceuticals business in the Americas, overseeing the company's operations in the US, Canada and Central and Latin America.

Dr Brunn first joined Bayer in 2011 as global head of primary care, based in Beijing, China, and has subsequently served as head of Bayer's pharmaceuticals commercial operations in Japan since 2013.

Prior to this, Dr Brunn was vice president of pharma, Asia-Pacific at Bausch & Lomb and served as global head of marketing at Basilea Pharmaceutica International, based in Basel, Switzerland.

He also brings branding and sales leadership experience from Novartis and Eli Lilly, and recently served as chairman of European Federation of Pharmaceutical Industries and Associations (EFPIA), Japan.

Dieter Weinand, president of Bayer's pharmaceutical division, said: “Carsten is a strategic and highly respected leader in the pharmaceutical industry and I'm delighted to have him lead the company's largest pharmaceutical business worldwide.

“Carsten's global perspective and proven track record of successful operational executive at the local level will be a critical asset to us as we continue to build on our current momentum in the US and across the Americas region.”

26th January 2017

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics